The novel severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is the cause of a rapidly spreading illness,coronavirus disease 2019(COVID-19),affecting more than seventeen million people around the world.Diagnos...The novel severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is the cause of a rapidly spreading illness,coronavirus disease 2019(COVID-19),affecting more than seventeen million people around the world.Diagnosis and treatment guidelines for clinicians caring for patients are needed.In the early stage,we have issued"A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus(2019-nCoV)infected pneumonia(standard version)";now there are many direct evidences emerged and may change some of previous recommendations and it is ripe for develop an evidence-based guideline.We formed a working group of clinical experts and methodologists.The steering group members proposed 29 questions that are relevant to the management of COVID-19 covering the following areas:chemoprophylaxis,diagnosis,treatments,and discharge management.We searched the literature for direct evidence on the management of COVID-19,and assessed its certainty generated recommendations using the Grading of Recommendations,Assessment,Development and Evaluation(GRADE)approach.Recommendations were either strong or weak,or in the form of ungraded consensus-based statement.Finally,we issued 34 statements.Among them,6 were strong recommendations for,14 were weak recommendations for,3 were weak recommendations against and 11 were ungraded consensus-based statement.They covered topics of chemoprophylaxis(including agents and Traditional Chinese Medicine(TCM)agents),diagnosis(including clinical manifestations,reverse transcription-polymerase chain reaction(RT-PCR),respiratory tract specimens,IgM and IgG antibody tests,chest computed tomography,chest X-ray,and CT features of asymptomatic infections),treatments(including lopinavirritonavir,umifenovir,favipiravir,interferon,remdesivir,combination of antiviral drugs,hydroxychloroquine/chloroquine,interleukin-6 inhibitors,interleukin-1 inhibitors,glucocorticoid,qingfei paidu decoction,lianhua qingwen granules/capsules,convalescent plasma,lung transplantation,invasive or noninvasive ventilation,and extracorporeal membrane oxygenation(ECMO)),and discharge management(including discharge criteria and management plan in patients whose RT-PCR retesting shows SARS-CoV-2 positive after discharge).We also created two figures of these recommendations for the implementation purpose.We hope these recommendations can help support healthcare workers caring for COVID-19 patients.展开更多
目的基于文献计量学和可视化分析探讨中医药干预冠心病临床研究的现状和热点,为临床治疗提供借鉴和参考。方法检索中国知网、维普网、万方数据知识服务平台、中国生物医学文献数据库、PubMed和Web of Science核心合集数据库2007年1月至2...目的基于文献计量学和可视化分析探讨中医药干预冠心病临床研究的现状和热点,为临床治疗提供借鉴和参考。方法检索中国知网、维普网、万方数据知识服务平台、中国生物医学文献数据库、PubMed和Web of Science核心合集数据库2007年1月至2024年5月收录的中医药干预冠心病临床研究文献。采用NoteExpress软件筛选并纳入文献,采用CiteSpace软件分析年发文量、作者、机构、期刊和关键词。结果筛选后最终纳入8187篇中文文献与126篇英文文献,年发文量波动较大。中英文文献发文量最多的作者分别为王阶、Xu Hao;中英文文献发表最多的机构分别是辽宁中医药大学附属医院、China Academy of Chinese Medical Sciences;中英文文献发表最多的期刊分别是《中西医结合心血管病电子杂志》和Chinese Journal of Integrative Medicine。关键词分析显示,心绞痛、心力衰竭、麝香保心丸、quality of life、blood stasis syndrome和myocardial infarction等频次较高;产生20个聚类与55个突现关键词。结论该领域的研究热点集中在原发病及并发症、辨证诊断、评估指标和中医药治疗等方面。展开更多
基金supported(in part)by the National Key Research and Development Program of China(2020YFC0845500)the Special Project for Emergency of Hubei Province(2020FCA008)the First Level Funding of the Second Medical Leading Talent Project in Hubei Province。
文摘The novel severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is the cause of a rapidly spreading illness,coronavirus disease 2019(COVID-19),affecting more than seventeen million people around the world.Diagnosis and treatment guidelines for clinicians caring for patients are needed.In the early stage,we have issued"A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus(2019-nCoV)infected pneumonia(standard version)";now there are many direct evidences emerged and may change some of previous recommendations and it is ripe for develop an evidence-based guideline.We formed a working group of clinical experts and methodologists.The steering group members proposed 29 questions that are relevant to the management of COVID-19 covering the following areas:chemoprophylaxis,diagnosis,treatments,and discharge management.We searched the literature for direct evidence on the management of COVID-19,and assessed its certainty generated recommendations using the Grading of Recommendations,Assessment,Development and Evaluation(GRADE)approach.Recommendations were either strong or weak,or in the form of ungraded consensus-based statement.Finally,we issued 34 statements.Among them,6 were strong recommendations for,14 were weak recommendations for,3 were weak recommendations against and 11 were ungraded consensus-based statement.They covered topics of chemoprophylaxis(including agents and Traditional Chinese Medicine(TCM)agents),diagnosis(including clinical manifestations,reverse transcription-polymerase chain reaction(RT-PCR),respiratory tract specimens,IgM and IgG antibody tests,chest computed tomography,chest X-ray,and CT features of asymptomatic infections),treatments(including lopinavirritonavir,umifenovir,favipiravir,interferon,remdesivir,combination of antiviral drugs,hydroxychloroquine/chloroquine,interleukin-6 inhibitors,interleukin-1 inhibitors,glucocorticoid,qingfei paidu decoction,lianhua qingwen granules/capsules,convalescent plasma,lung transplantation,invasive or noninvasive ventilation,and extracorporeal membrane oxygenation(ECMO)),and discharge management(including discharge criteria and management plan in patients whose RT-PCR retesting shows SARS-CoV-2 positive after discharge).We also created two figures of these recommendations for the implementation purpose.We hope these recommendations can help support healthcare workers caring for COVID-19 patients.
文摘目的基于文献计量学和可视化分析探讨中医药干预冠心病临床研究的现状和热点,为临床治疗提供借鉴和参考。方法检索中国知网、维普网、万方数据知识服务平台、中国生物医学文献数据库、PubMed和Web of Science核心合集数据库2007年1月至2024年5月收录的中医药干预冠心病临床研究文献。采用NoteExpress软件筛选并纳入文献,采用CiteSpace软件分析年发文量、作者、机构、期刊和关键词。结果筛选后最终纳入8187篇中文文献与126篇英文文献,年发文量波动较大。中英文文献发文量最多的作者分别为王阶、Xu Hao;中英文文献发表最多的机构分别是辽宁中医药大学附属医院、China Academy of Chinese Medical Sciences;中英文文献发表最多的期刊分别是《中西医结合心血管病电子杂志》和Chinese Journal of Integrative Medicine。关键词分析显示,心绞痛、心力衰竭、麝香保心丸、quality of life、blood stasis syndrome和myocardial infarction等频次较高;产生20个聚类与55个突现关键词。结论该领域的研究热点集中在原发病及并发症、辨证诊断、评估指标和中医药治疗等方面。
